Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib significantly decreased cell proliferation and phosphorylation leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlo-Stella, Carmelo, Locatelli, Silvia L., Giacomini, Arianna, Cleris, Loredana, Saba, Elena, Righi, Marco, Guidetti, Anna, Gianni, Alessandro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631141/
https://www.ncbi.nlm.nih.gov/pubmed/23620775
http://dx.doi.org/10.1371/journal.pone.0061603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631141/
https://www.ncbi.nlm.nih.gov/pubmed/23620775
http://dx.doi.org/10.1371/journal.pone.0061603

Ejemplares similares